Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.63 |
| ▸ | NPY1R | P25929 | 9/20 | 0.63 |
| ▸ | NPY2R | P49146 | 6/20 | 0.63 |
| ▸ | F2 | P00734 | 2/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371668 | 1.00 | NPY4R (0.63) | NPY4RNPY5RNPY1RNPY2RF2 | |
| SCHEMBL31229192 | 0.92 | F2 (0.59) | NPY4RNPY5RNPY1RNPY2RF2 | |
| SCHEMBL1370287 | 0.91 | NPY4R (0.72) | NPY4RNPY5RNPY1RNPY2RF2 | |
| SCHEMBL1370292 | 0.91 | NPY4R (0.72) | NPY4RNPY5RNPY1RNPY2RF2 | |
| SCHEMBL31060843 | 0.88 | NPY4R (0.63) | NPY4RNPY5RNPY1RNPY2RF2 | |
| SCHEMBL25626301 | 0.86 | ACE (0.63) | F2KISS1R | |
| SCHEMBL25626030 | 0.86 | ACE (0.63) | F2KISS1R | |
| SCHEMBL30405659 | 0.86 | NPY4R (0.53) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30541914 | 0.85 | NPY4R (0.59) | NPY4RNPY5RNPY1RNPY2RF2 | |
| SCHEMBL30064048 | 0.85 | NPY4R (0.59) | NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | NPY4R 39/4885NPY5R 92/4885NPY1R 22/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | NPY4R 39/4885NPY5R 92/4885NPY1R 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.